Disclosed positions

Estimated from their latest filings — positions may have changed since

$12.93M

combined est. value

Stock	Shares	Price	Value	Weight	As of
INSMINSMED Inc	97,723	$118.26	$11.56M	89%	2026-02-09
RYTMRHYTHM PHARMACEUTICALS, INC.	11,712	$115.48	$1.35M	10%	2026-06-23
XFORX4 Pharmaceuticals, Inc	4,722	$3.96	$18.7K	0%	2025-06-09

INSM

INSMED Inc

$11.56M

97,723 sh

RYTM

RHYTHM PHARMACEUTICALS, INC.

$1.35M

11,712 sh

XFOR

X4 Pharmaceuticals, Inc

$18.7K

4,722 sh

All filings on record

Every Form 4 transaction we track for this filer

all 10buys 0sells 4

Stock	Transaction	Date	~6mo later
RYTMRHYTHM PHARMACEUTICALS, INC.	Exercise — · 4,712 sh	2026-06-23	—
INSMINSMED Inc	Gift — · 53,400 sh	2026-02-09	—
INSMINSMED Inc	Gift — · 53,400 sh	2026-02-09	—
RYTMRHYTHM PHARMACEUTICALS, INC.	Exercise — · 4,000 sh	2025-06-18	—
XFORX4 Pharmaceuticals, Inc	Grant — · 1,500 sh	2025-06-09	—
INSMINSMED Inc	Sell $219.8K · 3,000 sh	2025-06-04	—
RYTMRHYTHM PHARMACEUTICALS, INC.	Sell $648.1K · 9,873 sh	2025-06-03	—
RYTMRHYTHM PHARMACEUTICALS, INC.	Sell $3.62M · 55,558 sh	2025-06-03	—
RYTMRHYTHM PHARMACEUTICALS, INC.	Exercise $300.3K · 65,431 sh	2025-06-03	—
INSMINSMED Inc	Sell $231.7K · 3,250 sh	2025-06-03	—

RYTMExercise

2026-06-23 · RHYTHM PHARMACEUTICALS, INC.

4,712

—

INSMGift

2026-02-09 · INSMED Inc

53,400

—

INSMGift

2026-02-09 · INSMED Inc

53,400

—

RYTMExercise

2025-06-18 · RHYTHM PHARMACEUTICALS, INC.

4,000

—

XFORGrant

2025-06-09 · X4 Pharmaceuticals, Inc

1,500

—

INSMSell

2025-06-04 · INSMED Inc

$219.8K

—

RYTMSell

2025-06-03 · RHYTHM PHARMACEUTICALS, INC.

$648.1K

—

RYTMSell

2025-06-03 · RHYTHM PHARMACEUTICALS, INC.

$3.62M

—

RYTMExercise

2025-06-03 · RHYTHM PHARMACEUTICALS, INC.

$300.3K

—

INSMSell

2025-06-03 · INSMED Inc

$231.7K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.